The present invention generally relates to a process for preparation of 9-halo-3-(2-haloacetyl)- 10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one of Formula I, which is an intermediate in the preparation of Hepatitis C Virus (HCV) inhibitors.
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
2.
NOVEL POLYMORPHS OF VEMURAFENIB, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF
The present invention relates to novel polymorphic Forms of vemurafenib, processes for its preparation and pharmaceutical composition containing the same.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
The present invention provides a method for the preparation of intermediates useful in the synthesis of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. It also provides a method of preparing gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate.
The present invention relates to an improved process for the preparation of macitentan and pharmaceutical acceptable salts thereof. Further present invention also relates to methylene chloride solvate of macitentan and their use in the preparation of pure macitentan.
The present invention provides an improved process for the preparation of Atorvastatin or pharmaceutically acceptable salts thereof in high yield and purity.
The present invention provides solid forms of SGLT2 inhibitors, to processes for their preparation and their use in the purification of SGLT2 inhibitors and also provided pharmaceutical compositions comprising them and their use in therapy.
The present invention relates to solid forms of Tenofovir alafenamide and salts thereof, particularly its monofumarate and its hemifumarate salts; processes for its preparation and pharmaceutical compositions thereof.
C07D 215/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
9.
NOVEL POLYMORPHS OF DOLUTEGRAVIR AND SALTS THEREOF
A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
10.
DACLATASVIR FREE BASE AND PROCESS FOR THE PREPARATION THEREOF
The present invention relates to daclatasvir free base, processes for its preparation, a process for its conversion into pharmaceutically acceptable salts of daclatasvir. The present invention also relates to a process for the preparation and purification of daclatasvir dihydrochloride.
The present invention relates to an improved process for the preparation of carfilzomib or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of amorphous form of carfilzomib.
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07D 303/36 - Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
The present invention provides novel intermediates of cobicistat or a pharmaceutically acceptable salt thereof and a process for its preparation. The present invention also provides for the preparation of cobicistat or a pharmaceutically acceptable salt thereof using the intermediates.
The present invention relates to processes for the preparation of rosuvastatin calcium of formula I and pharmaceutically acceptable salts thereof using novel intermediates, and to a pharmaceutical composition containing the same.
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
C07C 69/66 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
16.
A RECYCLING PROCESS FOR PREPARING (S)-2-[(SUBSTITUTED-PHENOXY)-PHENOXY- PHOSPHORYLAMINO] PROPIONIC ACID ISOPROPYL ESTER DIASTEREOMERS
The present invention relates to an efficient and economical process to recycle the desired diastereomer of (2-[(substituted–phenoxy)-phenoxy-phosphorylamino] propionic acid isopropyl ester of Formula I from undesired diastereomer by first racemization of the undesired diastereomer followed by separation of the desired diastereomer from the racemic mixture.
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
17.
NOVEL POLYMORPHS OF IVACAFTOR, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF
The present invention relates to novel polymorphic forms of ivacaftor, process for its preparation and pharmaceutical compositions comprising the same.
The present invention generally relates to an improved process for preparation of 5- Amino-2,4-di-tert-butylphenol or hydroxyl derivative thereof or an acid addition salt thereof, which is an intermediate of Ivacaftor. More specifically the present invention relates to a process for preparation of hydrochloric acid salt of 5-Arnino-2,4-di-tert- butylphenol.
The present invention relates to an improved process for the preparation of enzalutamide by conventional synthesis, which avoids utilization of microwave irradiation and noxious reagents. The present invention also relates to an improved process for preparation of 4- isothiocyanato-2-(trifluoromethyl) benzonitrile, which is an intermediate in the synthesis of Enzalutamide.
The present invention provides a process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate of Formula I in high yield and purity.
C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
The present invention relates to novel polzmorphs of tenofovir disoproxil oxalate, process for its preparation and pharmaceutical composition comprising the same.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
22.
NOVEL POLYMORPHS OF SITAGLIPTIN HYDROCHLORIDE, PROCESSES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF
The present invention relates to novel polymorphic forms of sitagliptin hydrochloride, processes for its preparation and pharmaceutical compositions comprising the same.
The present invention relates to efficient, environment friendly and economical processes for the preparation of vildagliptin without isolating the intermediate compounds. Also provided is a process for the recovery of expensive 1-aminoadamantane-3-ol and use thereof in the preparation of vildagliptin.
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 207/00 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
The present invention relates to a novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof using novel intermediates.
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
The present invention relates to a novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof using novel intermediates.
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
26.
A PROCESS FOR THE PREPARATION OF CRIZOTINIB OR AN ACID ADDITION SALT THEREOF
The present invention is relates to a process for the preparation of crizotinib or an acid addition salts thereof. More specifically the invention pertains to crizotinib free base in amorphous form and crizotinib dihydrochloride in crystalline and amorphous Forms and pharmaceutical compositions containing the same.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07C 33/46 - Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic part
27.
AN IMPROVED PROCESS FOR THE PREPARATION OF ABIRATERONE ACETATE
The present invention relates to an improved process for the preparation of abiraterone acetate. More specifically the invention relates to a process for the preparation of abiraterone acetate free from dimer and other impurities.
C07C 1/30 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from organic compounds containing only halogen atoms as hetero atoms by splitting-off the elements of hydrogen halide from a single molecule
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
C07C 2/84 - Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms by condensation of hydrocarbons with partial elimination of hydrogen oxidative coupling catalytic
The present invention relates to an improved process for the preparation of β-carotene having pharmaceutically acceptable level of residual solvent content.
C07C 1/34 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from compounds containing hetero atoms other than, or in addition to, oxygen or halogen reacting phosphines with aldehydes or ketones, e.g. Wittig reaction
C07C 403/24 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
C07C 2/36 - Catalytic processes with hydrides or organic compounds as phosphines, arsines, stilbines or bismuthines
29.
AN IMPROVED PROCESS FOR THE PREPARATION OF NILOTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
The present invention relates to an improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof, with high purity and yields.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 233/61 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
30.
A RECYCLING PROCESS FOR PREPARING TENOFOVIR ALAFENAMIDE DIASTEREOMERS
The present invention relates to an efficient and economical process to recycle the undesired diastereomer of Tenofovir alafenamide to desired diastereomer by racemization of the undesired diastereomer followed by separation of the desired diastereomer from the racemic mixture.
The present invention provides novel intermediates of vemurafenib or a pharmaceutically acceptable salt thereof and processes for its preparation. The present invention also provides novel processes for preparation of vemurafenib or a pharmaceutically acceptable salt thereof using the novel intermediates.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
32.
AN IMPROVED PROCESS FOR THE PREPARATION OF PAZOPANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
The present invention is relates to an improved process for the preparation of pazopanib or a pharmaceutically acceptable salts thereof. The present invention also relates to novel polymorphic Forms of pazopanib hydrochloride, and its intermediates thereof.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
33.
NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE NOREPHEDRINE AND ITS DERIVATIVES
The present invention relates to a novel process for preparation of norephedrine and its derivatives. The present invention also relates to a process for separation of individual isomers of norephedrine and its derivatives using suitable chiral resoluting agents.
C07C 215/02 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
The present invention relates to solid forms of curcumin and derivatives thereof, including polymorphs and co-crystals; process for their preparation and composition comprising them.
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 36/90 - Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
35.
AN IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR ALAFENAMIDE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
The present invention provides an improved process for the preparation of Tenofovir alafenamide or pharmaceutically acceptable salts thereof in high yield and purity. Also provided is a process for the separation of diastereomers of Tenofovir alafenamide by simulated moving bed chromatography or preparative high performance liquid chromatography.
The present invention relates to an improved process for the preparation of ticagrelor, which involves ecofriendly reaction solvent and bases. The present invention also relates to a process for preparation of ticagrelor in crystalline Form or an amorphous form.
The present invention relates to novel acid addition salts of dabigatran etexilate, process for the preparation and pharmaceutical compositions containing the same. Further, the invention relates to uses of said compositions for post operative prophylaxis of deep vein thrombosis and the prevention of strokes.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
38.
A PROCESS FOR PURIFICATION OF EFAVIRENZ AND INTERMEDIATES THEREOF USING CHROMATOGRAPHIC METHODS
The present invention relates to a process for the enantiomeric enrichment of efavirenz using chromatographic methods such as simulated moving bed chromatography and/or batch elution chromatography method.
The present invention relates to Sitagliptin lipoate salt and its polymorphic forms, a process for its preparation. The present invention also relates to a pharmaceutical composition using the Sitagliptin lipoate and its polymorphic forms.
C07D 471/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
40.
AN IMPROVED PROCESS FOR PREPARATION OF DABIGATRAN ETEXILATE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF
The present invention provides an improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof, particularly mesylate salt. The present invention also provides novel salts of intermediates of Dabigatran etexilate and their polymorphs.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
41.
AN IMPROVED PROCESS FOR THE PREPARATION OF EMTRICITABINE
C07D 411/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
42.
AN IMPROVED PROCESS FOR THE PREPARATION OF TRIPTOLIDE PRODRUGS
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
43.
SITAGLIPTIN PTEROSTILBENE PHOSPHATE SALT, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF
The present invention relates to Sitagliptin Pterostilbene phosphate salt and its polymorphic forms, a process for its preparation. The present invention also relates to a pharmaceutical composition using the Sitagliptin Pterostilbene phosphate and its polymorphic forms.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
C07C 43/215 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
C07F 9/12 - Esters of phosphoric acids with hydroxyaryl compounds
44.
A PROCESS FOR PREPARING ERLOTINIB HYDROCHLORIDE FORM A
The present invention relates to a process for preparing erlotinib hydrochloride Form A from a solvent mixture comprising dichloromethane, methyl tertiary butyl ether and isopropyl ether. HCl.
The present invention provides solid forms of cabazitaxel, processes for its preparation and pharmaceutical compositions containing the same. The present invention also provides an amorphous form and a process for its preparation and pharmaceutical compositions thereof.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
C07D 305/14 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
The present invention provides novel intermediates of ivacaftor and process for its preparation. The present invention also provides process for the preparation of ivacaftor and pharmaceutically acceptable salt thereof using novel intermediates.
The present invention relates to an improved process for the preparation of Metformin hydrochloride by removing solvent from a solution comprising metformin hydrochloride using agitated thin film dryer.
The present invention relates to an improved process for the preparation of Atazanavir bisulfate Form A. The present invention also relates to a pharmaceutical composition using the Atazanavir bisulfate Form A of the invention.
C07D 213/42 - Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
49.
SOLID FORMS OF TYROSINE KINASE INHIBITORS, PROCESS FOR THE PREPARATION AND THEIR PHARMACEUTICAL COMPOSITION THEREOF
The present invention generally relates to solid forms of tyrosine kinase inhibitors, in particular combinations of tyrosine kinase inhibitors with anti-oxidative acids, processes for its preparation and pharmaceutical compositions containing the same.
Provided are a process for preparation of darunavir or solvates or a pharmaceutically acceptable salt thereof substantially free of bisfuranyl impurities and a process for preparation of amorphous darunavir using the darunavir propionate solvate.
C07D 493/00 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
Disclosed is one pot process of the preparation of 2,3-dihydroxy benzonitrile from 2,3-dialkoxy benzoic acid without prior isolation of the intermediates. Further disclosed is the preparation of 2,3-dihydroxy benzonitrile by dealkylation of 2,3-dialkoxy benzonitrile using suitable aluminum salt-amine complex.
C07B 43/08 - Formation or introduction of functional groups containing nitrogen of cyano groups
C07C 209/50 - Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of carboxylic acid amides
C07C 233/65 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
C07C 235/46 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
Disclosed is a process for the preparation of montelukast sodium. The process comprises a) reacting 2-(2-(3(S)-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-hydroxypropyl)phenyl)-2-propanol with methane sulfonyl chloride and coupling the resultant mesylate compound with l-(mercaptomethyl)cyclopropane acetic acid in presence of a base and free alkali source followed by saltification with an amine in a single step reaction and b) converting the montelukast amine salt to montelukast sodium salt.
Disclosed is an improved process for the preparation of rilpivirine hydrochloride. The process comprises a) reacting 3-(4-amino-3,5-dimethyl phenyl)-acrylonitrile hydrochloride and 4-[(4-chloropyrimidin-2-yl) amino] benzonitrile in the presence of a phase transfer catalyst followed by saltification with an acid and b) converting the rilpivirine acid addition salt into rilpivirine hydrochloride salt.
The present invention relates to an improved process for the preparation of Erlotinib hydrochloride pure Form A. The present invention also provides a pharmaceutical composition using the erlotinib hydrochloride pure Form A of the invention.
The present invention relates to an improved process for the preparation of Sunitinb. The process involves the activation of 5-((Z)-(5-fluoro-2- oxoindolin-3-ylidene) methyl)-2,4- dimethyl-1 H-pyrrole-3carboxylic acid to corresponding suitable carboxylic acid activating group. The present invention also relates to novel acid addition salts of Sunitinb and preparation thereof.
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention provides tenofovir disoproxil phosphate and a process for its preparation. The present invention also provides a pharmaceutical composition using the tenofovir disoproxil phosphate of the invention.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
The present invention provides a process for preparation of Luteolin by deprotection of the corresponding ethers using Lewis acid mediated Ionic complexes, and to compositions containing the same.
C07D 311/30 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
C07C 45/65 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by splitting-off hydrogen atoms or functional groupsPreparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by hydrogenolysis of functional groups
C07C 49/82 - Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
C07C 39/14 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with at least one hydroxy group on a condensed ring system containing two rings
The present invention provides a process for the preparation of tenofovir. The present invention also provides a process for the preparation of tenofovir disoproxil or a salt thereof and its pharmaceutical composition using the tenofovir of the present invention.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
59.
PROCESS FOR PREPARATION OF POLYHYDROXYSTILBENE COMPOUNDS BY DEPROTECTION OF CORRESPONDING ETHERS
A process for the preparation of polyhydroxystilbene compounds (particularly resveratrol, oxyresveratrol, piceatannol, gnetol and the like) by deprotection of the corresponding ethers using aluminium halide and a secondary amine is provided.
C07C 37/01 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
C07C 39/21 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic part, with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
The present invention provides a process for preparation of tenofovir by dealkylation of its phosphonate ester using Ionic complexes. The present invention also provides a process for preparation of tenofovir disoproxil or a salt thereof using the tenofovir of the present invention.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
61.
NOVEL SALTS OF SITAGLIPTIN, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF
The present invention relates to pharmaceutically acceptable acid addition salts of sitagliptin, in particular anti-oxidant acid addition salts of sitagliptin and a process for its preparation. The present invention also provides a pharmaceutical composition using the pharmaceutically acceptable acid addition salts of sitagliptin.
The present invention provides processes for preparation of eptifibatide that involve coupling of amino acids in a (2+5), (4+3) and (3 +4) sequence method. The invention further provides products produced by the described processes, novel compounds that can be used as synthetic intermediates for the preparation of eptifibatide.
The present invention provides a process for the preparation of nevirapine, which comprises reaction of 2-chloro-N-(2-chloro-4-methyl-3-pyridinyl)-3-pyridine carboxamide with cyclopropyl amine in presence of a suitable reagent such as carbonates, bicarbonates, acetates of alkali metals and lanthanum oxide, followed by cyclization of the resultant product.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Disclosed are solid forms of antiretroviral compounds and anti-oxidative acids, and processes for their preparation. Pharmaceutical compositions using the solid forms are also disclosed.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
The present invention provides a novel crystalline form AL of bortezomib and a process for its preparation. The present invention also provides a pharmaceutical composition using the novel crystalline form AL of bortezomib.
The present invention provides a process for the preparation of tenofovir. The present invention also provides a process for the preparation of tenofovir disoproxil or a salt thereof and its pharmaceutical composition using the tenofovir of the present invention.
C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
Cocrystals of pterostilbene are disclosed, including: pterostilbene: caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene : glutaric acid cocrystal, and pterostilbene: piperazine cocrystal. The pterostilbene: caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene: caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals.
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A61P 39/06 - Free radical scavengers or antioxidants
patents
